Why Incyte Stock Lost 11% in April
What happened
Biotech specialist Incyte (NASDAQ: INCY) trailed the market last month as the stock shed 11%, compared to a 4% jump in the S&P 500, according to data provided by S&P Global Market Intelligence.
Shareholder returns are in solidly positive territory over the past year, though, with Incyte up 32% in that time, compared to an 8% increase in the broader market.
So what
Investors sent the stock lower in April as they braced for potentially bad news in the company's first-quarter earnings report. However, the actual results contained positive operating news. On April 30, executives revealed that a 20% increase in sales for its Jakafi treatment helped drive Incyte's sales higher by 30%. The development pipeline is packed with several potential commercial wins, including a cream that could treat vitiligo, a skin condition that affects pigmentation.
Now what
Investors will have to wait for more clinical results before judging the commercial strength of that cream and of Incyte's other treatments currently working their way toward Food and Drug Administration clearance. In the meantime, the company affirmed its sales outlook for Jakafi and still sees the drug delivering revenue of between $1.58 billion and $1.65 billion this year.
10 stocks we like better than IncyteWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Incyte wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of March 1, 2019
Demitrios Kalogeropoulos has no position in any of the stocks mentioned. The Motley Fool recommends Incyte. The Motley Fool has a disclosure policy.